Detail akcie 4D Molecular Rg online

Business Summary: 4D Molecular Therapeutics, Inc. is a late-stage biotechnology company advancing durable and disease-targeted therapeutics. The Company's lead product candidate 4D-150 is designed to be a backbone therapy forming the foundation of treatment of blinding retinal vascular diseases by providing multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C) with a single, safe, intravitreal injection, which substantially reduces the treatment burden associated with current bolus injections. Its lead indication for 4D-150 is wet age-related macular degeneration, which is in Phase III development, and second indication is diabetic macular edema. The Company is developing 4D-710 for the treatment of a range of people with cystic fibrosis independent of their specific CFTR mutation. 4D-710 is an investigational genetic medicine candidate using the A101 vector for the treatment of cystic fibrosis lung disease. The Company's non-core programs include 4D-175, 4D-725, and 4D-310.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, 4D Molecular Therapeutics Inc revenues increased from $36K to $119K. Net loss increased 43% to $159.5M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects BIOLOGICAL PRODUCTS segment loss increase of 32% to $174.3M. Basic Earnings per Share excluding Extraordinary Items decreased from -$2.08 to -$2.85.